Jiwanjeet Dhaliwall

TL;DR: In this paper, the authors report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate produced in plants that displays the SARS-CoV-2 spike glycoprotein (CoVLP: NCT04450004 ).

TL;DR: Two phase 3 efficacy studies of a recombinant quadrivalent virus-like particle (QVLP) influenza vaccine manufactured in plants in adults aged 18-64 years and 65-plus, showing relative vaccine efficacy to prevent laboratory-confirmed influenza-like illness caused by any influenza strain are described.

TL;DR: The CoVLP+AS03 vaccine was effective in preventing Covid-19 caused by a spectrum of variants, with efficacy ranging from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.

TL;DR: In this article, the authors evaluated the safety, tolerability, and immunogenicity of CoVLP at three dose levels (3.75 microgram, 7.5 microgram and 15 microgram) unadjuvanted or adjuvanted with either CpG 1018 or AS03.

TL;DR: The primary efficacy endpoint was prevention of symptomatic SARS-CoV-2 infection with onset at least 7 days after the second injection and was triggered by the identification of [≥]160 virologically-confirmed cases, and tolerability and safety of CoVLP+AS03 were also determined.